Epidemiological trends of hepatitis in mainland China: 2004–2019

Abstract

Hepatitis, caused by five main viral strains (A, B, C, D, and E), is a major global health issue in animals and humans. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are particularly concerning and can lead to chronic diseases, cirrhosis, liver cancer, and death. Recent WHO data indicate a rise in hepatitis-related deaths from 1.1 million (2019) to 1.3 million (2022), predominantly attributed to HBV. China bears a substantial global burden of HBV and HCV due to its large population. Data on hepatitis A, B, C, E, and unclassified hepatitis from 2004–2019 were obtained from the Chinese Center for Disease Control and Prevention. Joinpoint, ArcGIS, and SaTScan were used to analyze trends, spatial‒temporal distributions, and correlations. From 2004–2019, the overall incidence and mortality of viral hepatitis in China declined. Although hepatitis C and E showed an initial increase until 2012 before stabilizing. Hepatitis B remains the most common strain, with peaks in spring, particularly in the southeastern provinces (Jiangsu, Zhejiang, Fujian). Farmers and workers were the most affected groups due to their living and hygiene conditions. Spatial analysis revealed higher concentrations of cases in rapidly urbanizing and mobile regions. Enhanced prevention and control strategies targeting high-risk populations and regions are critical for reducing hepatitis transmission and improving public health in China.

The original online version of this article was revised: Equal contribution statement has been added. Figure 1, Figure 2, Figure 7, and Figure 8 have been updated. Figure 1, Figure 2, and Figure 3 captions have been updated.

A correction to this article is available online at https://doi.org/10.1186/s44149-025-00192-9.

Keywords

China / Hepatitis / Epidemiology / Spatiotemporal / Analysis

References

[1] AlvesJD, AbadeAS, PeresWP, BorgesJE, SantosSM, ScholzeAR. Impact of COVID-19 on the indigenous population of Brazil: A geo-epidemiological study. Epidemiology and Infection, 2021, 149e185.

[2] AndonovA, RobbinsM, BorlangJ, CaoJ, HatchetteT, StueckA, JohnstonL. Rat hepatitis E virus linked to severe acute hepatitis in an immunocompetent patient. Journal of Infectious Diseases, 2019, 220(6): 951-955.

[3] BaoY, LarneyS, PeacockA, ColledgeS, GrebelyJ, HickmanM, LeungJ. Incidence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. The International Journal on Drug Policy, 2019, 70: 87-93.

[4] BaoYP, LiuZM. Systematic review of HIV and HCV infection among drug users in China. International Journal of STD and AIDS, 2009, 20(6): 399-405.

[5] ChenS, LiJ, WangD, FungH, WongLY, ZhaoL. The hepatitis B epidemic in China should receive more attention. Lancet, 2018, 391101301572.

[6] CoulepisAG, LocarniniSA, WestawayEG, TannockGA, GustID. Biophysical and biochemical characterization of hepatitis A virus. Intervirology, 1982, 18(3): 107-127.

[7] CuiF, ShenL, LiL, WangH, WangF, BiS, WangY. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy. China. Emerg Infect Dis, 2017, 23(5): 765-772.

[8] CunninghamC. Accelerating the elimination of viral hepatitis for Indigenous peoples. Lancet Gastroenterol Hepatol, 2019, 4(2): 93-94.

[9] DegenhardtL, CharlsonF, StanawayJ, LarneyS, AlexanderLT, HickmanM, VosT. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: Findings from the Global Burden of Disease Study 2013. The Lancet Infectious Diseases, 2016, 16(12): 1385-1398.

[10] EvonDM, StewartPW, AmadorJ, SerperM, LokAS, SterlingRK, FriedMW. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multicenter observational study. PLoS ONE, 2018, 138e0196908.

[11] GowerE, EstesC, BlachS, Razavi-ShearerK, RazaviH. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology, 2014, 61(1 Suppl): S45-57.

[12] HamiltonEM, RassamW, YanY, SinghA, NgSYA, ZhangJ, ChenZ. Correlates of chronic hepatitis B virus infection in the general adult population of China: Systematic review and meta-analysis. Journal of Viral Hepatitis, 2023, 30(6): 470-488.

[13] KaneMA, HadlerSC, LeeL, ShapiroCN, CuiF, WangX, KumarR. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization. Vaccine, 2013, 31(Suppl 9): J15-20.

[14] KimSJ, SiJ, LeeJE, KoG. Temperature and humidity influences on inactivation kinetics of enteric viruses on surfaces. Environmental Science and Technology, 2012, 46(24): 13303-13310.

[15] KulldorffM, HuangL, PickleL, DuczmalL. An elliptic spatial scan statistic. Statistics in Medicine, 2006, 25(22): 3929-3943.

[16] LiHZ, DuLB. Application of joinpoint regression model in cancer epidemiological time trend analysis. Zhonghua Yu Fang Yi Xue Za Zhi, 2020, 54(8): 908-912.

[17] LiM, WangZQ, ZhangL, ZhengH, ZhouMG, LiuDW. Burden of viral hepatitis caused by specific etiologies in China, 1990–2016: Findings from the GBD 2016. BMC Public Health, 2020, 2011461.

[18] LiM, ZhaoL, ZhouJ, SunY, WuX, OuX, JiaJ. Changing clinical care cascade of patients with chronic hepatitis B in Beijing. China. Lancet Reg Health West Pac, 2021, 16100249.

[19] LiQ, LiuM, ZhangY, WuS, YangY, LiuY, GuoX. The spatiotemporal analysis of the incidence of tuberculosis and the associated factors in mainland China, 2009–2015. Infection, Genetics and Evolution, 2019, 75103949.

[20] LiangX, BiS, YangW, WangL, CuiG, CuiF, WangY. Epidemiological serosurvey of hepatitis B in China–declining HBV incidence due to hepatitis B vaccination. Vaccine, 2009, 27(47): 6550-6557.

[21] LiaoX, LiangZ. Strategy vaccination against Hepatitis B in China. Human Vaccines & Immunotherapeutics, 2015, 11(6): 1534-1539.

[22] LiuJ, LiangW, JingW, LiuM. Countdown to 2030: Eliminating hepatitis B disease. China. Bull World Health Organ, 2019, 97(3): 230-238.

[23] LiuZ, YangQ, ShiO, YeW, ChenX, ZhangT. The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: An observational population-based study. Journal of Viral Hepatitis, 2018, 25(12): 1543-1554.

[24] LongKZ, NanthakumarN. Energetic and nutritional regulation of the adaptive immune response and trade-offs in ecological immunology. American Journal of Human Biology, 2004, 16(5): 499-507.

[25] LawMan John, L., Landi, A., Magee, W. C., Lorne Tyrrell, D., & Houghton, M. . Progress toward a hepatitis C virus vaccine. Emerg Microbes Infect., 2013, 211e79.

[26] MatareseG, La CavaA. The intricate interface between immune system and metabolism. Trends in Immunology, 2004, 25(4): 193-200.

[27] MbithiJN, SpringthorpeVS, SattarSA. Effect of relative humidity and air temperature on survival of hepatitis A virus on environmental surfaces. Applied and Environment Microbiology, 1991, 57(5): 1394-1399.

[28] Mohd HanafiahK, GroegerJ, FlaxmanAD, WiersmaST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroincidence. Hepatology, 2013, 57(4): 1333-1342.

[29] Mollalo, A., Mao, L., Rashidi, P., & Glass, G. E. 2019. A GIS-based artificial neural network model for spatial distribution of tuberculosis across the continental United States. Int J Environ Res Public Health, 16 (1). https://doi.org/10.3390/ijerph16010157

[30] Murphy, E. L., Bryzman, S. M., Glynn, S. A., Ameti, D. I., Thomson, R. A., Williams, A. E., Nemo, G. J. 2000. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology, 31 (3), 756–762. https://doi.org/10.1002/hep.510310329

[31] NjugunaHN, HiebertL, HarrisA, MorganRL, GuptaN, WardJW. An assessment of national strategic action plans for viral hepatitis elimination, 2016–2021. Journal of Infectious Diseases, 2023, 228(Suppl 3): S148-S153.

[32] OdenwaldMA, PaulS. Viral hepatitis: Past, present, and future. World Journal of Gastroenterology, 2022, 28(14): 1405-1429.

[33] PintoRM, CostafredaMI, BoschA. Risk assessment in shellfish-borne outbreaks of hepatitis A. Applied and Environment Microbiology, 2009, 75(23): 7350-7355.

[34] Polaris ObservatoryC. Global incidence, treatment, and prevention of hepatitis B virus infection in 2016: A modeling study. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403.

[35] Polaris ObservatoryC. Global incidence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modeling study. Lancet Gastroenterol Hepatol, 2023, 8(10): 879-907.

[36] QinQQ, GuoW, WangLY, YanRX, GeL, WangL, CuiY. [Epidemiological characteristics of hepatitis C in China, 1997–2011. Zhonghua Liu Xing Bing Xue Za Zhi, 2013, 34(6): 548-551

[37] RenX, WuP, WangL, GengM, ZengL, ZhangJ, YuH. Changing epidemiology of hepatitis A and hepatitis E viruses in China, 1990–2014. Emerging Infectious Diseases, 2017, 23(2): 276-279.

[38] SanchezG, PintoRM, VanaclochaH, BoschA. Molecular characterization of hepatitis a virus isolates from a transcontinental shellfish-borne outbreak. Journal of Clinical Microbiology, 2002, 40(11): 4148-4155.

[39] SchaubelDE, TranAH, AbtPL, PotluriVS, GoldbergDS, ReesePP. Five-year allograft survival for recipients of kidney transplants from hepatitis C virus infected vs uninfected deceased donors in the direct-acting antiviral therapy era. JAMA, 2022, 328(11): 1102-1104.

[40] ShanS, CuiF, JiaJ. How to control highly endemic hepatitis B in Asia. Liver International, 2018, 38(Suppl 1): 122-125.

[41] SmithDB, BukhJ, KuikenC, MuerhoffAS, RiceCM, StapletonJT, SimmondsP. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology, 2014, 59(1): 318-327.

[42] SuX, ZhengL, ZhangH, ShenT, LiuY, HuX. Secular trends of acute viral hepatitis incidence and mortality in China, 1990 to 2019 and its prediction to 2030: The global burden of disease study 2019. Front Med (Lausanne), 2022, 9842088.

[43] The Lancet Infectious, D. 2022. Explaining the unexplained hepatitis in children. Lancet Infect Dis. 22 (6): 743. https://doi.org/10.1016/S1473-3099(22)00296-1

[44] Vilinova, K. 2020. Spatial autocorrelation of breast and prostate cancer in Slovakia. Int J Environ Res Public Health, 17 (12). https://doi.org/10.3390/ijerph17124440

[45] WangAL, QiaoYP, WangLH, FangLW, WangF, JinX, SongL. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China. Bulletin of the World Health Organization, 2015, 93(1): 52-56.

[46] WangY, WangM, ZhangG, OuX, MaH, YouH, JiaJ. Control of chronic hepatitis B in China: Perspective of diagnosis and treatment. China CDC Wkly, 2020, 2(31): 596-600.

[47] WuZ, CuiF, ChenY, MiaoN, GongX, LuoH, YangW. Evaluation of immunization injection safety in China, 2010: Achievements, future sustainability. Vaccine, 2013, 31(Suppl 9): J43-48.

[48] YangS, WuJ, DingC, CuiY, ZhouY, LiY, LiL. Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: An observational trend study. The Lancet Infectious Diseases, 2017, 17(7): 716-725.

[49] ZengN, ZouC, HeZ, MaH, OuX, YouH, JiaJ. Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. International Journal of Infectious Diseases, 2018, 67: 58-64.

[50] ZhangS, WangF, ZhangZ. Current advances in the elimination of hepatitis B in China by 2030. Frontiers in Medicine, 2017, 11(4): 490-501.

[51] ZhaoN, GuoX, WangL, ZhouH, GongL, MiaoZ, WangS. Changing spatiotemporal patterns for hepatitis of unspecified etiology in China, 2004–2021: A population-based surveillance study. Frontiers in Public Health, 2023, 111177965.

[52] ZhuD, GuoN, WangJ, NicholasS, WangZ, ZhangG, WangenKR. Socioeconomic inequality in Hepatitis B vaccination of rural adults in China. Human Vaccines & Immunotherapeutics, 2018, 14(2): 464-470.

[53] Daniel, Castaneda Adalberto Jose, Gonzalez Mohammad, Alomari Kanwarpreet, Tandon Xaralambos Bobby, Zervos (2021) From hepatitis A to E: A critical review of viral hepatitis World Journal of Gastroenterology 27(16) 1691-1715 10.3748/wjg.v27.i16.1691

Funding

National Natural Science Foundation of China(32202857)

Science and Technology Program of Hubei Province(2024BBB073)

RIGHTS & PERMISSIONS

The Author(s)